Down-regulation of autoantibody levels of cyclosporine and bromocriptine treatment in patients with uveitis.
The administration of cyclosporine A, cyclosporine A plus bromocriptine, or bromocriptine results in down-regulation of antinuclear autoantibody levels in the sera of patients with uveitis. Decreased levels of autoantibodies against DNA, histones, cardiolipin, RNP, Sm, Ro (SS-A), and La (SS-B) were detected in the sera of patients with uveitis receiving cyclosporine A or cyclosporine A plus bromocriptine following 3 months of treatment. In contrast to the decreased antibody titers obtained following the treatment, the total immunoglobulin levels remained within the normal range. The results indicate that cyclosporine may affect B cell function, thereby yielding the observed decrease in autoantibody levels. This phenomenon might have clinical importance as a serological indicator of the efficiency of the patients to respond to the drug.
Blank
M
M
Department of Medicine D, Soroka Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Palestine
A
A
Nussenblatt
R
R
Shoenfeld
Y
Y
D001323:Autoantibodies / Q000032:analysis*; D001971:Bromocriptine / Q000008:administration & dosage / Q000627:therapeutic use*; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D015536:Down-Regulation; D004359:Drug Therapy, Combination; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D014605:Uveitis / Q000188:drug therapy / Q000276:immunology*
D001323:Autoantibodies; D003524:Cyclosporins; D007136:Immunoglobulins; D001971:Bromocriptine